Objective: Circulating adrenal steroids rise during the menopausal transition in most middle-aged women and may contribute to differences in between-women symptoms and ultimate health outcomes. However, the mechanisms for this shift in adrenal steroid production in middle-aged women are not known. This study aims to determine whether hormone therapy (HT) for 1 year can modulate adrenal androgen production.
R ecent studies of women monitored longitudinally have identified a previously unrecognized increase in adrenal androgen secretion in the perimenopausal period, reversing the long age-related decline of the decades 1,2 and thereby implicating adrenal function as a component of the menopausal transition (MT). The MT begins in the late reproduc-tive period in women, who may still exhibit normal cyclicity but experience menopause-associated symptoms, including vasomotor instability, insomnia, and dysphoria. 3 The pathophysiology underlying menopausal symptoms and response to therapy remains unclear. 4 For instance, recent prospective studies failed to find any specific cycle characteristics related to the most consistent perimenopausal complaints (hot flashes and night sweats or hormonal patterns) that predicted with much certainty the final progression to the menopause. 5 Although symptomatic women are most often treated with some form of estrogen replacement, 6, 7 estradiol (E 2 ) concentrations are normal or even elevated in perimenopausal women 8 and are seldom low in fact. Furthermore, the lack of symptoms in women who have low estrogen levels even several years after menopause suggests that E 2 deficiency alone is not the cause and that estrogen therapy comes with obvious health risks. 9 The most common adrenal androgens, dehydroepiandrosterone (DHEA) and its sulfoconjugate, dehydroepiandrosterone sulfate (DHEAS), although potential substrates for estrogen and biopotent androgen synthesis, have not proven to be of benefit in the treatment of menopausal symptoms. 10 However, other androgens from the adrenal gland, such as androst-5-ene-3A,7A-diol (Adiol), circulate in women 11 at levels capable of providing estrogenic stimulation when E 2 concentrations are very low. 12 Therefore, adrenal androgens may modulate estrogenic status and help explain the incongruence between menopausal symptoms and circulating E 2 concentrations. The rhesus macaque has proven useful as a model of human menopause, 13<16 as it has for fetal adrenal androgen secretion, 17, 18 adrenal development in infancy, 19<22 and adrenal aging. 23<25 Studies in rhesus macaques may shed light on the variety and variability among adrenal androgens through the transition and thereby suggest the possible value of alternative therapies for perimenopausal and postmenopausal women.
Combined oral contraceptives suppress DHEAS concentrations in women 26<33 and have been used, in part, to lower androgen concentrations in patients with polycystic ovarian syndrome. 34, 35 Exactly how, mechanistically, steroidal treatment influences adrenal androgen secretion remains unknown. Although rhesus macaques have been used to examine the cognitive and neural benefits of hormone therapy (HT), 36 the effects of estrogen plus progesterone (E + P) treatment on adrenal androgen secretion have not been investigated in this model. Because age affects the ability of estrogen-alone (E) treatment to improve cognition in older but not younger female macaques, the current study was conducted to determine how different HT regimens affect adrenal steroid production. We hypothesize that HT would modulate adrenal androgen production in the absence of ovaries, but that the response would change with age. We tested this hypothesis by examining the effects of HT on younger and older ovariectomized (OVX) female rhesus macaques.
METHODS

Animals
The study used OVX younger female rhesus macaques (Macaca mullata) with a mean (SE) age of 9.8 (0.4) years (n = 15) and OVX older female macaques with a mean (SE) age of 22.7 (0.4) years (n = 22) years in the treatment experiment. Animal assignments were randomized by the animal technician, and the investigators were blinded to those assignment codes.
An older intact group (25.1 [0.4] years, n = 7) was used as age control reference point. All animals were either grouphoused during early social development or wild-caught and maintained in rooms where they have visual, olfactory, and auditory contacts with each other. The experimental history of each animal was reviewed to exclude animals previously used for behavioral research, studies involving potentially neurotoxic agents, and studies that may have affected reproductive function. All macaques were pair-housed for a minimum of 6 months before entering the protocol, remaining with their cage mate during the day and separated at night (to facilitate monitoring of food consumption and urine collection). Before inclusion in the research project, all animals received thorough physical examinations, including complete blood count, complete serum chemistry including fasting blood glucose, screen for type D simian retrovirus, ophthalmologic examination, and assessment of physical capability to perform behavioral tasks (eg, exclusion of advanced arthritis). Animals infected with type D retrovirus (positive polymerase chain reaction result), eye lesions such as cataracts, or metabolic disorders such as diabetes were also excluded from the project.
Individual animals were selected for entry into the study based on confirmation of ovarian function by hormonal analysis. Ovarian function tests in candidate animals were performed not only to confirm reproductive status but also to monitor the effectiveness of ovariectomy and hormone exposure treatments. Overnight urine samples were collected daily and frozen until analyzed for major estrogen (E1C) and progesterone (PdG) metabolites normalized to creatinine. A second category of endocrine evaluation was conducted to verify the efficacy of treatment regimens. Each hormone regimen resulted in characteristic hormone levels that were easily distinguishable and comparable to the serum levels expected as a consequence of the respective treatments. The treatments consisted of continuous E and E + P. Young female macaques (n = 5 per group) were treated for a total of 216 days. Old female macaques were treated, on average, for 564 days with either vehicle (n = 8), E (n = 8), or E + P (n = 6). E was administered using subcutaneous Silastic capsules to achieve approximately 150 pg/mL concentrations in serum. Silastic implants were placed subcutaneously between the shoulder blades under ketamine (10 mg/kg) and medetomidine (0.2-0.4 mg/kg) sedation, with atipamezole (0.2-0.4 mg/kg) given at the end of the procedure to reverse medetomidine. The dose of micronized progesterone was 10 to 20 mg/day given orally for a 10-day interval once each month to reach circulating levels of 4 to 8 ng/mL. The study was reviewed and approved by the University of California Davis Institutional Animal Care and Use Committee.
Hormone assays
Blood was collected by venipuncture and allowed to clot. Sera were collected after centrifugation and stored frozen until assayed. DHEAS was measured by competitive chemiluminescent immunoassay on a Bayer Diagnostic ACS-180 automated analyzer, as reported previously. 2 For DHEAS assay, the intra-assay and interassay coefficients of variation were 2.9% and 6.9%, respectively. The limit of detection was 1.0 Kg/dL. Androstenedione (Adione), testosterone, DHEA, and Adiol were analyzed in serum by radioimmunoassay with preceding organic solvent extraction and Celite column partition chromatography steps. The assay sensitivities were 0.03, 0.15, 0.2, and 0.03 ng/mL, respectively, with interassay coefficients of variation ranging from 8% to 13%.
Histology
Animals were euthanized and fixed by perfusion under deep anesthesia after completing the treatment protocol. Animals were anesthetized with ketamine (10 mg/kg) and pentobarbital (60 mg/kg) and perfused transcardially with 1% paraformaldehyde for 1 minute, followed by 4% paraformaldehyde in 0.1 M phosphate buffer for 12 minutes at a flow rate of 225 to 250 mL/min. Adrenal glands were dissected and processed for routine histology. Tissues were embedded carefully to allow uniform sectioning along the long axis of the gland, and 5-Km sections were cut and stained with hematoxylin-eosin from which the zona glomerulosa, zona fasciculata (ZF), zona reticularis (ZR), and medulla could be identified. Images were captured using a Zeiss Lumar V12 stereo motorized microscope, with a Zeiss AxioCam HRc Rev3 color camera and NeoLumar S 1.5Â lens (total magnification, 200Â) that allowed visualization of whole adrenal cross-sections in one picture. The cortical zones were defined based on staining intensity using Image-Pro Plus 5.0 analysis software (Media Cybernetics, Silver Spring, MD), and zonal areas were estimated ( Fig. 1 ). Areas of each zone were calculated and expressed as a percentage of the total cortical area.
Statistics
Data were analyzed by one-way analysis of variance using the general linear models function of SAS, version 9.3 (SAS Institute, Cary, NC). Values were log transformed, where indicated, by existing heterogeneity of variance. The main effects of age, treatment, and age-treatment interaction were included in the model statement. Comparisons among means were examined using Tukey's honest significance multiple-range test, and rs were calculated among androgens and between androgens and ZR area.
RESULTS
Aged intact and aged vehicle-treated OVX female macaques had similar concentrations of DHEAS, DHEA, and Adiol. DHEAS concentrations were 10-fold higher than DHEA, and DHEA was approximately 3-fold higher than Adiol, which was still in the nanograms-per-milliliter range ( Table 1) . Adione and testosterone concentrations averaged less than 1 ng/mL. DHEAS concentrations were significantly higher in young intact female macaques (before ovariectomy) than in older intact female macaques (12 [1. 70] ng/mL, P G 0.05), in animals receiving vehicle, but there were no statistically significant differences in Adiol, Adione, or testosterone (Table 1) , although the mean Adiol was twice as high in OVX younger animals. All androgen concentrations in younger and older OVX female macaques were positively correlated with one another (r = 0.34-0.81, P G 0.05), with two exceptions: DHEAS was not correlated with either Adione (P 9 0.50) or testosterone (P 9 0.05), and the highest correlations found were between DHEAS and DHEA (r = 0.70, P G 0.001) and between DHEA and Adiol (r= 0.81, P G 0.001).
HT intervention had a significant effect on DHEAS concentrations in both younger and older OVX female macaques (Fig. 2 ). E and E + P treatments decreased DHEAS concentrations to a similar degree in young female macaques. In old Androgen concentrations in aged intact (n = 7), aged OVX (n = 8; OVX), and young (n = 5; OVX) vehicle-treated female rhesus macaques. Significance levels (P) for comparisons between the concentrations of steroids in aged and young female macaques are shown in the last column. OVX, ovariectomized; DHEAS, dehydroepiandrosterone sulfate; DHEA, dehydroepiandrosterone; Adione, androstenedione; Testost, testosterone; Adiol, androst-5-ene-3A,7A-diol. female macaques, DHEAS concentrations were similar between vehicle-treated and E-treated participants. DHEAS concentrations in female macaques receiving E + P treatment were marginally higher than in vehicle-treated female macaques (P G 0.06) but significantly elevated over those of the E-treated female macaques (P G 0.01). The difference in response to E + P with ageVyoung female macaques suppressing DHEAS but old female macaques tending to stimulate itVwas supported statistically by a significant interaction between age and treatment (P G 0.01). Despite the high correlations between DHEAS and both DHEA and Adiol, these treatment effects did not reach statistical significance.
Comparisons between younger (n = 5) and older (n = 8) vehicle-treated participants (Fig. 1 ) by image analysis of adrenal histology indicated that ZR area as a percentage of the total cortical area was greater in younger female macaques than in aged female macaques (46.8% [4.9%] vs 29.0% [4.3%], respectively, P G 0.025), but there was no difference by age in ZF area (38.3% [4.2%] vs 48.8% [3.7%], respectively, P 9 0.05). Histological data were not available for a sufficient number of adrenal specimens from younger female macaques in the HT groups to allow for a valid analysis, but there was no detectable effect of HT on ZR or ZF area in older female macaques (P 9 0.1). However, circulating DHEAS levels were positively correlated with ZR area across young and old female macaques (r = 0.47, P G 0.01) and negatively correlated with ZF area (r = j0.37, P G 0.05). There were no statistically significant correlations found between ZR area and the other androgens.
DISCUSSION
The current study is the first to examine the concentrations of various adrenal androgens in younger and older rhesus macaques uncomplicated by any contribution from the gonads, and to examine the effects of extended HT. As expected from numerous previous studies, 22 ,37<39 DHEAS concentra-tions were 3-fold higher in young female macaques than in aged female macaques, DHEA in young female macaques was more than twice that in old female macaques, and Adiol was marginally higher in young rhesus macaques, but testosterone and Adione did not differ by age. DHEAS was positively correlated with ZR area and, as a percentage of cortical area, was higher in younger female macaques than in older female macaques, indicating that the age-related decline in DHEAS secretion is probably associated with shrinking of ZR. This is consistent with the reduction in ZR width 40 and in the expression of enzymes in ZR involved in the synthesis of DHEAS. 41 The relative concentrations of DHEAS and unconjugated DHEA in younger and older female primates differed somewhat from those in women. As adults, rhesus macaques have lower DHEAS concentrations but higher DHEA concentrations than humans. 42 The ratios of conjugated to unconjugated DHEA do not differ substantially by age or treatment between humans and rhesus macaques. However, this analysis provides evidence that OVX rhesus macaques have circulating levels of Adiol that are considerably higher than those found in women 11 and would be expected to transduce signals through estrogen receptors (ERs). 12 In this study, we use circulating DHEAS as a surrogate for adrenal steroids, which may influence the symptoms and health outcomes of women during the MT.
Of additional interest were the observed effects of HT on adrenal androgen concentrations and the possible differences in response between younger and older OVX female macaques. Estrogen inhibited DHEAS concentrations in younger female macaques and marginally so in older female macaques, as numerous studies in humans have demonstrated, 27<34 but the addition of progesterone to estrogen seemed to have a different effect on old versus young participants. Specifically, treatment of old female macaques with E + P reversed the inhibition that E treatment exerted. Female macaques treated with E + P also had marginally (P G 0.06) higher concentrations of DHEAS than vehicle-treated controls, although not reaching significance. No rescue of DHEAS occurred in young female macaques treated with E + P, which inhibited DHEAS concentrations as effectively as E treatment. This may simply reflect the much shorter period of treatment in younger female macaques compared with older female macaques, although they were still treated for more than 7 months. The differential effects of E versus E + P treatment on stimulating DHEAS in older female macaques can clearly not be ascribed to effects on the ovaries themselves, which, in postmenopausal women with intact ovaries, would be difficult to discern even if such data were at hand. In the absence of the ovaries, an effect of aging on the hypothalamus, as others have observed in nonhuman primates, 25 must be suspected. Alternatively, a change in receptor expression in the adrenal cortex itself might alter adrenal sensitivity to trophic stimulation. Ovariectomy alone would be expected to increase gonadotropin concentrations but not pro-opiomelanocortin concentrations. 43 It must be noted that not all studies have reported inhibition as a consistent response to E treatment in women. 44, 45 Slayden et al 46 found no changes in adrenal androgen concentrations and adrenal responsiveness to adrenocorticotropic hormone (ACTH) stimulation, but this was after only 3 months of therapy. The mechanism by which the addition of progesterone to E treatment in older female macaques reverses the inhibition of DHEAS by E treatment remains unknown to date.
These findings may also shed some light on the mechanisms by which the acceleration in adrenal androgen production in middle-aged women might contribute to their endocrine milieu. 12 The age-related decline in adrenal androgen is reversed in a majority of women during early perimenopause, when follicle-stimulating hormone (FSH) also begins to rise. This timing suggests that the decline in some ovarian component triggers the release of inhibition on adrenal androgen secretion. The increase in adrenal androgens in women continues through the MT and plateaus at or after menopause, suggesting that some nonovarian component provides a stimulus. 2 In this study, we use circulating DHEAS as a surrogate for adrenal steroids, which may influence the symptoms and health outcomes of women during the MT. Although no similar spontaneous age-related rise and plateau in adrenal androgens were identified in the current study of aged rhesus monkeys, ovarian activity was confirmed in all animals at enrollment; therefore, none were postmenopausal when the study began. Shideler et al 25 investigated circulating DHEAS levels in similarly aged female rhesus macaques stratified by ovarian status. Upon comparison with normally cyclic female macaques, those with abnormal cycles and those that were anovulatory had elevated levels of FSH, lower inhibin B levels, and numerically higher circulating concentrations of DHEAS. Thus, the older animals in this study were apparently functionally younger than the animals that Shideler et al 25 identified as having increased adrenal androgens and as being functionally younger than women during the MT. 2 In the present study, estrogen replacement alone accelerated the decline in adrenal androgen production in younger female macaques and also in older female macaques (Fig. 2 ) in the absence of ovaries. In contrast, E + P was not as effective in suppressing DHEAS in younger animals and maintained it at preovariectomy levels in older animals. Thus, although cyclic ovarian function is not essential for the increase in adrenal androgens after ovariectomy in women, 47 it is apparently able to prevent the continuous fall that would occur in its absence in this animal model, with treatment extending for a year and a half in older female macaques. This observation suggests that different HT regimens may provide different benefits to perimenopausal and postmenopausal women by the degree of support they offer to adrenal androgen synthesis.
Taken together, these data reveal that different HT regimens have different effects on adrenal steroidogenesis in adult female primates and may have clinical relevance to women during the MT in connection to neurological changes and breast cancers. E treatment decreases adrenal androgens as shown previously in women, 44, 45 and this suppression of adrenal androgen production may explain the lack of nonneoplastic adverse effects of E treatment compared with combination replacement regimens. In contrast, E + P replacement may increase the full complement of adrenal androgens, including DHEA and Adiol, and, most importantly, shift the circulating ER->YER-A ligand balance in favor of ER-A, with several potential implications. 48 First, the increase in ZR thickness associated with E + P indicates a shift in adrenal steroidogenesis from the $ 5 pathway to the $ 4 pathway, thereby increasing the need for additional ACTH stimulation to keep circulating cortisol at minimally normal levels. Such a Bresetting[ of the hypothalamic-pituitary-adrenal axis has been associated with depression in middle-aged women but was never sufficiently explained. 49 The shift in the capacity of the adrenal cortex to respond to metabolic and environmental stressors may explain why there is a paradoxical increase in ACTH in such disorders during the MT in women. Second, ER-A agonists such as Adiol have been associated with changes in spine density and glutaminergic signaling that are opposite to the positive effects of those reported for E 2 . 50 Thus, the cyclic nature of E 2 during the MT, in association with increasing Adiol, may explain discrepancies in the failure to associate various symptoms with the measurement of circulating E 2 . Third, several recent reports have associated estrogen-plus-progestogen therapies with an increase in breast cancers in postmenopausal women. 51 More importantly, tissue levels of DHEA and Adiol in tumor tissues have been detected at levels considered effective for Adiol to support cell proliferation in ER->Ypositive cells in the absence of E 2 . 52, 53 Because Adiol does not require aromatization for its ER signaling activity, increased circulating levels, as promoted by combination HT, could support some types of breast cancer growth.
The extreme variability of symptoms and the underlying endocrinology of women in the MT remain a mystery. The late reproductive period is marked most consistently by increasing FSH concentrations and decreasing inhibin B levels. 54 Despite having E 2 concentrations similar to those in younger women, some perimenopausal women have a longer follicular phase and an unusually thick endometrium in the luteal phase, 55 consistent with excessive estrogen-stimulated uterine growth. In any event, perimenopause does not seem to be a period of estrogen deficiency, and although estrogen replacement is often prescribed, it is rarely given with regard to a verifiable estrogen deficit. Results of recent longitudinal studies on large numbers of women enrolled in the Study of Women's Health Across the Nation indicate that the MT involves a previously unrecognized but significant involvement of androgen secreted by ZR. Examination of longitudinal hormone data from the Study of Women's Health Across the Nation reveals that most women (,85%) traversing the MT experienced a transient increase in $ 5 adrenal steroids, namely, Adiol and DHEA. 12 This increase in $ 5 C-19 steroid secretion represents a major hormone dynamic during the MT that may have clinical relevance. Adiol has both androgenic and estrogenic bioactivities 12 and reaches effective circulating concentrations in some women. 11 Its weak ER-> potential may well contribute positively to circulating estrogenicity, particularly when circulating E 2 levels are low, 12 but its ER-A activity may contribute a wide range of effects depending on the tissue concentrations of specific receptors.
Summary
The present data demonstrate that the ZR of female macaques undergoes diminution in both size and androgen synthetic capacity during the second decade of life. In addition, these results show striking similarities in relative circulating concentration and source of adrenal androgens between macaques and middle-aged women. A modest ovarian contribution of DHEAS and a more robust amount of Adione in circulating levels are indicated for macaques after the ovariectomy of older animals, similar to that shown for women. 12 Intervention with E treatment in OVX macaques results in an accelerated decline in ZR function in both young and older female macaques. In contrast, intervention with E + P restored and tended to enhance adrenal androgen concentrations after a year and a half of treatment in older animals.
CONCLUSIONS
Female macaques provide an appropriate animal model for investigating age-related changes in ZR function that have been observed in middle-aged women. Intervention with typical HT regimens can modulate ZR structure and function with potentially different effects on younger versus older animals.
